R. Amaria

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study”.

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study

The Oncologist(2021)10.1002/onco.13795

N/A

0DataRank · unranked

43 citations

Douglas B. Johnson, Ryan J. Sullivan, R. Amaria, Keith T. Flaherty, Jeffrey A. Sosman +2 more

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1170

N/A

0DataRank · unranked

4 citations

James W. Smithy, Christy Los, Hannah L. Kalvin, Nathan Hasson, R. Amaria +15 more

Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier

Nutrients(2025)10.3390/nu18010040

N/A

0DataRank · unranked

1 citations

Satabdi Saha, Nazli Dizman, Michelle Rohlfs, Elizabeth Sirmans, J. M. Gardner +17 more